Researchers at the University of British Columbia (UBC), in collaboration with the Berlin Institute of Health at Charité in Germany, have developed the first CRISPR-based gene-editing therapy delivered topically to human skin. The treatment corrects disease-causing mutations directly in skin tissue and was detailed in a study published on January 27, 2026, in Cell Stem Cell .

The approach uses lipid nanoparticles to carry a CRISPR base editor through the skin surface, targeting stem cells in the epidermis to repair faulty genes. In laboratory-grown human skin models, the therapy restored up to 30% of normal skin function in models of autosomal recessive congenital ichthyosis (ARCI).

The Breakthrough in Topical Delivery

Traditional gene therapies require invasive delivery methods such as injections or viral vectors. This study demonstrates that topical application — similar to a cream — achieves therapeutic gene correction without systemic exposure. Lipid nanoparticles penetrate the skin barrier and deliver an engineered cytosine base editor (eTd-CBE), which precisely changes a single DNA base to correct the most common mutation in ARCI without cutting both DNA strands.

The editing remained localized to the skin with no detectable off-target effects in the tested models. On-target editing reached up to 26% in patient-derived keratinocytes, with no bystander edits observed — one of the first demonstrations of therapeutic splice-site repair using a cytosine base editor.

This represents a significant technical advance. Previous gene-editing therapies for skin conditions relied on ex vivo editing — removing cells, correcting them in a lab dish, and reintroducing them — or on systemic delivery that exposes the entire body to the editing machinery. Delivering the correction directly through the skin surface simplifies administration and confines the intervention to the target tissue.

Targeted Disease: Autosomal Recessive Congenital Ichthyosis (ARCI)

The proof-of-concept focused on ARCI, a rare inherited disorder that causes severe dry, scaling skin due to mutations in genes responsible for skin barrier function. The therapy corrected the most frequent mutation, restoring enzyme activity and skin barrier integrity in human skin-on-a-chip models.

ARCI affects a small patient population globally. The condition currently has no cure, and management is limited to emollients, keratolytics, and systemic retinoids — none of which address the underlying genetic defect. Topical gene correction, if translated to patients, would change that calculus entirely.

The research team noted that while ARCI was the initial target, the platform shows potential for adaptation to other genetic skin disorders, including epidermolysis bullosa (EB), and possibly more common inflammatory conditions such as eczema and psoriasis.

Key Technical Specifications

The delivery system includes:

Lipid nanoparticles optimized for skin penetration, bypassing the epidermal barrier without irritation or systemic leakage.
CRISPR base editor (eTd-CBE) targeting the specific cytosine-to-thymine mutation most common in ARCI — no double-strand DNA breaks required.
No viral vectors, significantly reducing immunogenicity risks and simplifying regulatory pathways.
One-time application potential — because epidermal stem cells are corrected, the therapeutic effect may be durable as corrected cells repopulate the skin surface.

The absence of viral delivery is particularly important. Viral vectors, while effective at gene delivery, carry risks of immune responses and have historically complicated the clinical development of gene therapies. A lipid nanoparticle formulation is already widely accepted clinically — the same class of delivery system used in mRNA COVID-19 vaccines — though skin penetration at therapeutic doses remains an active area of development.

The Research Team and Senior Authorship

Senior author Dr. Sarah Hedtrich, Associate Professor at UBC's School of Biomedical Engineering , stated that the treatment corrects the root cause of disease and may provide lasting benefits from a single application. The study is the result of a multi-year collaboration between UBC and the Berlin Institute of Health at Charité – Universitätsmedizin Berlin , one of Europe's largest academic medical centers.

The team combined expertise in CRISPR base editing, lipid nanoparticle formulation, dermatology, and skin stem cell biology — a multidisciplinary approach that enabled both the scientific advance and the translational roadmap toward clinical trials.

Path to Clinical Trials: Epithelica

The research team has spun out a startup called Epithelica to advance the technology toward clinical trials. The company is built around the topical gene-editing platform and is working to develop it as a commercial therapeutic.

Discussions with regulatory authorities are underway to define the pathway for first-in-human studies. The approach is described as safe, scalable, and easy to use, with potential for broader application across the spectrum of dermatological gene editing.

Rare disease designations — such as Orphan Drug status in the U.S. and EU — could accelerate the regulatory path for an ARCI indication, given the small patient population and lack of curative options.

Broader Implications for Genetic Skin Diseases

This marks the first demonstration of topical CRISPR delivery achieving functional gene correction in human skin models. The localized nature minimizes off-target risks and simplifies administration compared to injections or viral methods — advantages that matter both clinically and regulatorily.

If translated to patients, the platform could address both rare monogenic disorders and, through repeated or adjusted applications, potentially polygenic conditions. The skin-on-a-chip model used to demonstrate efficacy and safety is a validated preclinical platform, though animal studies and first-in-human trials remain ahead before clinical conclusions can be drawn.

The broader field of in vivo gene editing at epithelial surfaces — skin, lung, gut — has gained momentum with lipid nanoparticle delivery. This study is among the most clinically compelling proofs of concept yet published, combining precision base editing with a non-invasive delivery route and a clear disease target.

When CRISPR goes from injection to lotion bottle, the only thing left to edit might be the pharmacy shelf.